Decadron

(dexamethasone)

ApprovedSmall molecule

Dexamethasone is a steroid medication used to reduce inflammation and suppress the immune system in conditions like arthritis, allergies, asthma, and certain cancers. It's also used to reduce swelling in the brain and to help manage severe COVID-19 symptoms.[2] Decadron is currently approved and in use across 420 indications[4].[1]

Decadron is one of 4116 small molecule programs targeting Insulin resistance. It is currently in Approved.

420

Indications

2,271

Total Trials

Active Trials

4,115

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceActive, not recruiting

GliomaActive, not recruiting

ArthropathyActive, not recruiting

CellulitisActive, not recruiting

Plantar FasciitisActive, not recruiting

Wrist FractureApproved

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

MalnutritionActive, not recruiting

CalcificationActive, not recruiting

Premature BirthApproved

Insulin ResistancePhase 1

Active, not recruiting

GliomaPhase 1

Active, not recruiting

ArthropathyPreclinical

Active, not recruiting

CellulitisPreclinical

Active, not recruiting

Plantar FasciitisPhase 2

Active, not recruiting

Wrist FractureApproved

Approved

Childhood Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

MalnutritionPreclinical

Active, not recruiting

CalcificationPhase 2/Phase 3

Active, not recruiting

Premature BirthApproved

Approved

Showing 10 of 410 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

10 2

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 3

Ablavar

LLantheus Medical Imaging

Preclinical

2 4

Leronlimab

CCytoDyn, Inc.

Preclinical

1 5

Promestriene

UUniversity of Sao Paulo General Hospital

Preclinical

1 6

Therapeutic Progesterone

EEmory University

Preclinical

1 7

Mitoquinone

OOregon Health and Science University

Preclinical

1 8

Trastuzuma

FFudan University

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Treatment

NCT05668455

Phase 1Active, not recruiting

AL Amyloidosis

NCT04754945

Phase 2Active, not recruiting

Multiple Myeloma

NCT02253316

Q4 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT04925193

Phase 1/2Recruiting

Acute Lymphoblastic Leukemia

NCT06207123

Phase 1Active, not recruiting

Multiple Myeloma

NCT04091126

Clinical

Trials by Indication[1]

Multiple Myeloma53 trials

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05020236·944 enrolled

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02101944·12 enrolled

Show 50 more trials

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Completed·WWake Forest University Health Sciences·Phase 1/2·NCT03773107·12 enrolled

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Completed·UUniversity of Washington·Phase 2·NCT01110135·43 enrolled

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06948084·80 enrolled

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

Terminated·OOncopeptides AB·Phase 1/2·NCT01897714·75 enrolled

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00452569·499 enrolled

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Withdrawn·TThe Cleveland Clinic·Phase 2·NCT00112879

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00813150·96 enrolled

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT02633059·33 enrolled

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Unknown status·OOncotherapeutics·Phase 2·NCT00742404·35 enrolled

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Completed·MMayo Clinic·Phase 2·NCT00558896·378 enrolled

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed· Roche logo

Roche·Phase 1·NCT02431208·85 enrolled

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 1/2·NCT01677858·116 enrolled

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT03457142·15 enrolled

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04091126·118 enrolled

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00401843·307 enrolled

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01711528·41 enrolled

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00609167·63 enrolled

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT04802356·50 enrolled

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

Completed· Amgen logo

Amgen·Phase 3·NCT01568866·929 enrolled

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Withdrawn·KKathleen Dorritie·Phase 1/2·NCT06050512

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT02253316·236 enrolled

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01080391·792 enrolled

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06140966·54 enrolled

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT04270409·337 enrolled

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

No longer available·—··NCT02666209

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Active, not recruiting·—·Phase 2·NCT04756401·52 enrolled

Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma

Unknown status·JJinling Hospital, China·Phase 3·NCT02248428·130 enrolled

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Completed· GSK logo

GSK·Phase 1/2·NCT03544281·153 enrolled

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Unknown status·HHellenic Society of Hematology·Phase 1/2·NCT05280275·36 enrolled

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00319865·47 enrolled

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00833833·259 enrolled

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT00335348·101 enrolled

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Recruiting·EEmory University·Phase 2·NCT04776395·68 enrolled

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Recruiting·—·Phase 2·NCT06505369·50 enrolled

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT01962792·84 enrolled

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01246063·40 enrolled

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Withdrawn· AbbVie logo

AbbVie·Phase 2·NCT03785184

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Recruiting· AbbVie logo

AbbVie·Phase 1/2·NCT06892522·440 enrolled

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Terminated·UUniversity of Southern California·Phase 2·NCT01518465·13 enrolled

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Recruiting·—·Phase 2/3·NCT05665140·100 enrolled

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Terminated·OOncopeptides AB·Phase 3·NCT04649060·54 enrolled

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05236621·85 enrolled

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01440582·77 enrolled

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma

Completed·KKing's College Hospital NHS Trust·Phase 1/2·NCT00915408·32 enrolled

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00718640·10 enrolled

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting· AbbVie logo

AbbVie·Phase 2/3·NCT07095452·660 enrolled

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 3·NCT01850524·705 enrolled

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04925193·18 enrolled

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02252172·737 enrolled

Acute Lymphoblastic Leukemia12 trials

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Completed·MMehrdad Abedi, MD·Phase 1·NCT02293109·10 enrolled

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01190930·9,350 enrolled

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00671034·166 enrolled

Show 9 more trials

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recruiting·UUniversity of Chicago·Phase 1/2·NCT06207123·15 enrolled

Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

Unknown status·TTongji Hospital·Phase 4·NCT02690922·40 enrolled

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00390793·107 enrolled

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02003222·488 enrolled

Dexamethasone11 trials

Epidural Dexamethasone Versus Betamethasone for Treatment of Lumbosacral Radiculalgia

Unknown status·BBasque Health Service·Phase 4·NCT02833116·320 enrolled

Fascia Iliaca Block Supplemented With Perineural Vs Intravenous Dexamethasone

Unknown status·—·Phase 4·NCT04561856·99 enrolled

Dexamethasone Dose in Low Volume Bupivacaine USG Supraclavicular Block

Unknown status·EEslam Ayman Mohamed Shawki·Phase 4·NCT03043495·40 enrolled

Show 8 more trials

The Effectiveness of Preemptive Nebulized Dexamethasone in Reducing Post-Operative Sore Throat in Supraglottic Airway

Completed·UUniversiti Sains Malaysia·N/A·NCT04771026·140 enrolled

rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Completed·SShandong University·Phase 3·NCT01734044·158 enrolled

Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes

Unknown status·UUniversity of Calgary·Phase 4·NCT01024075·40 enrolled

Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP

Unknown status·SShandong University·Phase 3·NCT03252457·200 enrolled

Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%

Completed·UUniversity of Pennsylvania·N/A·NCT01690663·89 enrolled

Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors

Active, not recruiting·—·Phase 2·NCT05139043·26 enrolled

Dexamethasone & Ketamine as Adjuvants to Bupivacaine for Incisional Infiltration in Pediatric Abdominal Operations

Completed·—·N/A·NCT05190952·150 enrolled

Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)

Completed·UUniversity Hospitals Coventry and Warwickshire NHS Trust·Phase 1·NCT03341676·10 enrolled

Lymphoma11 trials

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Completed·WWashington University School of Medicine·Phase 1·NCT02181218·24 enrolled

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT05459571·35 enrolled

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 3·NCT02631239·256 enrolled

Show 8 more trials

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02703272·72 enrolled

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 1·NCT00598169·23 enrolled

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04917250·15 enrolled

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT02436707·129 enrolled

Primary Systemic Amyloidosis4 trials

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Completed·SSWOG Cancer Research Network·Phase 2·NCT00002849·93 enrolled

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

Completed·PPETHEMA Foundation·Phase 2·NCT01194791·30 enrolled

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Completed·MMayo Clinic·Phase 3·NCT00477971·89 enrolled

Show 1 more trial

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089167

91 more indications

Relapsed or Refractory3 trials

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT01903811·143 enrolled

Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL

Unknown status·PProf. Dr. M. Dreyling (co-chairman)·Phase 3·NCT01449344·128 enrolled

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Recruiting·AAbdullah Khan·Phase 1·NCT05981209·27 enrolled

Total Knee Arthroplasty3 trials

Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population

Unknown status·UUniversity of Puerto Rico·Phase 4·NCT06042426·100 enrolled

MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty

Completed·MMayo Clinic·Phase 4·NCT02739035·130 enrolled

Oral Dexamethasone as an Intervention for Postoperative Pain and Nausea Management in Total Knee Arthroplasty

Not yet recruiting·HHenry Ford Health System·Phase 4·NCT04432259·300 enrolled

Nausea and vomiting3 trials

Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00880191·430 enrolled

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Terminated·UUniversity of Washington·Phase 2·NCT00895245·6 enrolled

Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Children

Completed·TTanta University·Phase 1·NCT05124067·4 enrolled

Leukemia3 trials

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005977·83 enrolled

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

Unknown status·GGrupo Argentino de Tratamiento de la Leucemia Aguda·Phase 2/3·NCT00002499

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Unknown status·HHannover Medical School·Phase 2·NCT00002532

Prostate Cancer2 trials

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Completed·AAchieve Life Sciences·Phase 3·NCT01188187·1,022 enrolled

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

Completed· Sanofi logo

Sanofi·Phase 4·NCT02441894·21 enrolled

Chemotherapy2 trials

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Completed·MM.D. Anderson Cancer Center·N/A·NCT00410488·51 enrolled

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

Completed·SSun Yat-sen University·Phase 3·NCT03674294·248 enrolled

Maintenance Therapy2 trials

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

The PROLONG Trial - Rituximab Maintenance Therapy in ITP

Unknown status·OOstfold Hospital Trust·Phase 3·NCT03010202·136 enrolled

Hematological Malignancies2 trials

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Completed· Sanofi logo

Sanofi·Phase 1/2·NCT01084252·351 enrolled

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Terminated· Amgen logo

Amgen·Phase 1·NCT03465540·24 enrolled

Spinal Anesthesia2 trials

Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering

Completed·—·Phase 4·NCT03679065·300 enrolled

Intravenous Dexamethasone for Prolonging Sensory Block in Spinal Anesthesia

Completed·TTunis University·N/A·NCT07088432·120 enrolled

Myeloid Malignancies2 trials

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06383572·44 enrolled

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06930651·42 enrolled

Mantle Cell Lymphoma2 trials

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Unknown status·MMedical University of Vienna·Phase 2·NCT00261612·16 enrolled

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041132·56 enrolled

AL amyloidosis2 trials

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Recruiting·YYongyong MA·N/A·NCT06455748·20 enrolled

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Active, not recruiting·EEmory University·Phase 1·NCT04754945·11 enrolled

COVID-192 trials

Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19

Terminated·—·Phase 4·NCT04325061·19 enrolled

Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19

Completed·—·Phase 4·NCT04663555·235 enrolled

Lung Cancer2 trials

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT04267913

Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

Recruiting·PPeking University First Hospital·N/A·NCT04209218·1,988 enrolled

Systemic1 trial

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Not yet recruiting·—·Phase 1·NCT07341867·90 enrolled

Pain Control1 trial

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

Completed·—·Phase 1/2·NCT03040011·79 enrolled

Tonsillectomy1 trial

An Approach to Reduce Uvula Edema After Tonsillectomy

Completed·—·Phase 4·NCT03079453·30 enrolled

Randomized1 trial

A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

Completed·SShandong University·Phase 2·NCT01965626·96 enrolled

Age-Related Macular Degeneration1 trial

Combined Therapy in Age-Related Macular Degeneration (ARMD)

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00805649·150 enrolled

Thyroid Surgery1 trial

Ultrasound Guided Intermediate Cervical Plexus Block in Thyroid Surgery

Completed·—·N/A·NCT03731468·60 enrolled

Vomiting1 trial

The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain

Completed·UUniversity of Colorado, Denver·Phase 4·NCT04563494·127 enrolled

Post-cesarean Pain1 trial

Postoperative Dexamethasone on Post-Cesarean Pain

Completed·YYale University·Phase 4·NCT04067609·24 enrolled

Complication1 trial

The Effect of Perioperative DEXamethasone on Postoperative Complications After PANcreaticoduodenectomy

Completed·RRuijin Hospital·Phase 4·NCT05567094·300 enrolled

Subarachnoid Hemorrhage1 trial

Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage

Unknown status·UUniversity Hospital, Bonn·Phase 3·NCT05132920·334 enrolled

Urinary Tract Infection1 trial

Corticosteroids for Children With Febrile Urinary Tract Infections

Completed·NNader Shaikh·Phase 3·NCT01391793·546 enrolled

Lung Inflammation1 trial

Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment

Completed·MMedical University of Vienna·N/A·NCT01714427·36 enrolled

Steroid Injection1 trial

An Evaluation of Blood Glucose Levels and Insulin Requirement After Subacromial Corticosteroid Injection in Insulin Dependent Diabetics

Withdrawn·UUniversity of Pittsburgh·N/A·NCT03328975

Contracture1 trial

Ultrasound Guided Treatment of Steroids for Capsular Contracture in Patients With Reconstructed/Augmented Breast

Unknown status·RRabin Medical Center·N/A·NCT03171974·30 enrolled

Hematologic Malignancies1 trial

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT05476770·54 enrolled

Steroid1 trial

Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

Not yet recruiting·UUniversity of Nebraska·Phase 1/2·NCT06574048·20 enrolled

Advanced Solid Cancers1 trial

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Completed·HHenlix, Inc·Phase 1·NCT02648490·19 enrolled

Prophylaxis1 trial

Palonosetron Associated to Aprepitant in Prophylaxis of PONV

Unknown status·IInstituto do Cancer do Estado de São Paulo·Phase 4·NCT02431286·90 enrolled

Neonatal respiratory distress1 trial

Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000563

Refractory1 trial

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Recruiting·NNanjing IASO Biotechnology Co., Ltd.·Phase 3·NCT06464991·240 enrolled

Local Infiltration1 trial

Dexamethasone Versus Local Infiltration Technique for Tonsillectomy in Children

Completed·MMakassed General Hospital·N/A·NCT02355678·129 enrolled

Radius Fracture1 trial

Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures

Recruiting·CC. Liam Dwyer·Phase 4·NCT03898154·200 enrolled

Dexmedetomidine1 trial

Dexamethasone vs Dexmedetomidine vs Combination as Adjuvants to Popliteal Sciatic Nerve Block in Children

Recruiting·PPoznan University of Medical Sciences·N/A·NCT07289620·120 enrolled

Completed·MMayo Clinic·Phase 1·NCT01722305·29 enrolled

T-cell acute lymphoblastic leukemia1 trial

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02518750·3 enrolled

Pneumonia1 trial

Santeon-CAP; Dexamethasone in Community-acquired Pneumonia

Terminated·SSt. Antonius Hospital·Phase 4·NCT01743755·413 enrolled

Myelosuppression1 trial

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT00482261·150 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Safety and Efficacy1 trial

OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye

Completed·OOcular Therapeutix, Inc.·Phase 2·NCT02468700·43 enrolled

Infusion1 trial

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

Terminated·OOncopeptides AB·Phase 2·NCT04412707·27 enrolled

Sleep Restriction1 trial

Hormonal Mechanisms of Sleep Restriction - Axis Study

Active, not recruiting·PPeter y. Liu·Phase 1·NCT03142893·80 enrolled

Breast Cancer1 trial

TPI 287 in Breast Cancer Metastatic to the Brain

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01332630·24 enrolled

Amyloidosis1 trial

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Terminated·OOncopeptides AB·Phase 1·NCT04115956·6 enrolled

Pilot Study1 trial

A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL

Active, not recruiting·HHuashan Hospital·Phase 1·NCT05036577·15 enrolled

Post Operative Cognitive Dysfunction1 trial

Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction

Completed·UUniversity of Sao Paulo·Phase 4·NCT01332812·300 enrolled

Colorectal Cancer1 trial

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00026234·75 enrolled

Glioblastoma1 trial

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Withdrawn·—·Phase 1·NCT05773664

Liver Cancer1 trial

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00410956·22 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04546399·461 enrolled

Aspirin1 trial

Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM

Completed·UUniversity of Cape Town·Phase 2·NCT03927313·52 enrolled

Wet Age-Related Macular Degeneration1 trial

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Completed· AbbVie logo

AbbVie·Phase 2·NCT00775411·44 enrolled

Chemotherapy-induced nausea and vomiting1 trial

Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 3·NCT02484911·120 enrolled

Chronic Graft Versus Host Disease1 trial

Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease

Completed·GGrupo de Estudos Multicentricos em Onco-Hematologia·Phase 3·NCT01699412·28 enrolled

Metastatic Urothelial Cancer1 trial

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00479089·50 enrolled

Injury1 trial

Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06410443·60 enrolled

Myeloma1 trial

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00002548·899 enrolled

Cryptococcal Meningitis1 trial

Dexamethasone in Cryptococcal Meningitis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000776·36 enrolled

Meconium Aspiration Syndrome1 trial

Efficacy of Dexamethasone in Treatment of Meconium Aspiration Syndrome

Completed·SServices Institute of Medical Sciences, Pakistan·N/A·NCT05517499·120 enrolled

Advanced Cancer1 trial

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00060944·271 enrolled

Post Operative Sore Throat1 trial

Combined Effect of Dexamethasone and Paracetamol for Postoperative Sore Throat

Unknown status·SSeoul National University Hospital·N/A·NCT02252419·242 enrolled

Macroglobulinemia1 trial

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT02400437·26 enrolled

Supraclavicular Brachial Plexus Block1 trial

Peri-neural Dexmedetomidine Versus Dexamethasone for Supraaclavicular Block Adjuvant to Bupivacaine Supraclavicular Brachial Plexus Block

Completed·—·N/A·NCT04694105·42 enrolled

Newly Diagnosed1 trial

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Completed·TThe Catholic University of Korea·Phase 2·NCT01004497·51 enrolled

Relapsed/Refractory1 trial

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Completed·—·Phase 1·NCT03349281·6 enrolled

Myeloproliferative Disorder1 trial

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Completed·—·Phase 2·NCT00274820·15 enrolled

Intravenous Lidocaine1 trial

Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.

Terminated·JJeremy Kearns·Phase 4·NCT04208516·17 enrolled

Knee Arthroplasty1 trial

High-Dose Steroid for Knee Arthroplasty

Completed·—·Phase 4·NCT03758170·160 enrolled

Cognitive Dysfunction1 trial

Cognitive Dysfunction Following Cardiac Surgery

Unknown status·—·Phase 4·NCT02767713·171 enrolled

Glucocorticoids1 trial

Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD

Completed·VVA Office of Research and Development·N/A·NCT01090180·129 enrolled

Trial1 trial

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Completed· Astellas logo

Astellas·Phase 2·NCT02057380·13 enrolled

Germ Cell Tumor1 trial

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Completed·LLawrence Einhorn·Phase 2·NCT01736917·65 enrolled

Epiretinal membrane1 trial

Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

Terminated·WWills Eye·N/A·NCT02995746·3 enrolled

Adolescent Idiopathic Scoliosis1 trial

Postoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients

Not yet recruiting·—·Phase 4·NCT06023043·100 enrolled

Cataract1 trial

PRevention of Macular EDema After Cataract Surgery

Completed·MMaastricht University Medical Center·Phase 3·NCT01774474·1,127 enrolled

Hypospadias1 trial

Effect of Intravenous Dexamethasone With Pudendal Nerve Block on Postoperative Pain in Pediatric Hypospadias Repair

Completed·DDr Sonia ben khalifa (PhD)·Phase 4·NCT03902249·70 enrolled

Biomarkers1 trial

Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures

Completed·UUniversity of Michigan·Phase 1·NCT01673087·256 enrolled

Advanced Solid Tumors1 trial

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Terminated· AbbVie logo

AbbVie·Phase 1/2·NCT02709889·200 enrolled

Breast Surgery1 trial

Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery

Unknown status·—·N/A·NCT03480308·1 enrolled

Oral Lichen Planus1 trial

Treatment Modalities of Oral Lichen Planus

Unknown status·UUniversity of Faisalabad·Phase 1·NCT03237533·32 enrolled

Elderly Patients1 trial

Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

Terminated·GGeriatric Oncology Consortium·Phase 2·NCT00215748·40 enrolled

Minimal Residual Disease1 trial

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Treatment1 trial

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

Recruiting·AAgnes·Phase 3·NCT05668455·30 enrolled

Efficacy and Safety1 trial

Antiemetic Efficacy and Safety of Dexamethasone in Obstetric Surgical Patients

Completed·MMakerere University·N/A·NCT01028547·250 enrolled

Chidamide1 trial

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564704·80 enrolled

Unspecified1 trial

GEM-CLARIDEX: Ld vs BiRd

Unknown status·PPETHEMA Foundation·Phase 3·NCT02575144·286 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DECADRON

NDA NDA012376

Jan 1, 1982

HEXADROL

NDA NDA012674

Jan 1, 1982

DECADERM

NDA NDA013538

Jan 1, 1982

DECADRON

NDA NDA012071

Jan 1, 1982

DECADRON-LA

NDA NDA016675

Jan 1, 1982

HEXADROL

NDA NDA014694

Jan 1, 1982

DECADRON

NDA NDA011977

Jan 1, 1982

DECADRON

NDA NDA011984

Jan 1, 1982

MAXIDEX

NDA NDA013422

Jan 1, 1982

DECADRON

NDA NDA011664

Jan 1, 1982

DEXACORT

NDA NDA013413

Jan 1, 1982

HEXADROL

NDA NDA012675

Jan 1, 1982

DEXACORT

NDA NDA014242

Jan 1, 1982

DECASPRAY

NDA NDA012731

Jan 1, 1982

DECADRON

NDA NDA011983

Jun 17, 2009

OZURDEX

NDA NDA022315

Feb 9, 2018

DEXYCU KIT

NDA NDA208912

Nov 30, 2018

DEXTENZA

NDA NDA208742

Oct 3, 2019

HEMADY

NDA NDA211379

Sources

References

[1]
ClinicalTrials.gov — 2271 trial records for dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Decadron drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA211379). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Decadron. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Aspen Global Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAspen Global Incorporated

Patent Landscape[6]

Patent Cliff

Feb 12, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8563027Feb 12, 2030

8409606May 14, 2030

10799642May 11, 2032

10028965May 23, 2034

10159683May 23, 2034

7 more patents

10022502Jun 22, 2034

12150896Oct 7, 2036

11458041Nov 16, 2037

11304961Dec 18, 2037

10537585Dec 18, 2037

11097061Jun 23, 2039

12144889Apr 26, 2041

Decadron

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Multiple Myeloma53 trials

Acute Lymphoblastic Leukemia12 trials

Dexamethasone11 trials

Lymphoma11 trials

Primary Systemic Amyloidosis4 trials

Relapsed or Refractory3 trials

Total Knee Arthroplasty3 trials

Nausea and vomiting3 trials

Leukemia3 trials

Prostate Cancer2 trials

Chemotherapy2 trials

Maintenance Therapy2 trials

Hematological Malignancies2 trials

Spinal Anesthesia2 trials

Myeloid Malignancies2 trials

Mantle Cell Lymphoma2 trials

AL amyloidosis2 trials

COVID-192 trials

Lung Cancer2 trials

Systemic1 trial

Pain Control1 trial

Tonsillectomy1 trial

Randomized1 trial

Age-Related Macular Degeneration1 trial

Thyroid Surgery1 trial

Vomiting1 trial

Post-cesarean Pain1 trial

Complication1 trial

Subarachnoid Hemorrhage1 trial

Urinary Tract Infection1 trial

Lung Inflammation1 trial

Steroid Injection1 trial

Contracture1 trial

Hematologic Malignancies1 trial

Steroid1 trial

Advanced Solid Cancers1 trial

Prophylaxis1 trial

Neonatal respiratory distress1 trial

Refractory1 trial

Local Infiltration1 trial

Radius Fracture1 trial

Dexmedetomidine1 trial

Peripheral Nerve Block1 trial

Diffuse Large B-Cell Lymphoma1 trial

Central Nervous System Lymphoma1 trial

T-cell acute lymphoblastic leukemia1 trial

Pneumonia1 trial

Myelosuppression1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Safety and Efficacy1 trial

Infusion1 trial

Sleep Restriction1 trial

Breast Cancer1 trial

Amyloidosis1 trial

Pilot Study1 trial

Post Operative Cognitive Dysfunction1 trial

Colorectal Cancer1 trial

Glioblastoma1 trial

Liver Cancer1 trial

B-cell acute lymphoblastic leukemia1 trial

Aspirin1 trial

Wet Age-Related Macular Degeneration1 trial

Chemotherapy-induced nausea and vomiting1 trial

Chronic Graft Versus Host Disease1 trial

Metastatic Urothelial Cancer1 trial

Injury1 trial

Myeloma1 trial

Cryptococcal Meningitis1 trial

Meconium Aspiration Syndrome1 trial

Advanced Cancer1 trial

Post Operative Sore Throat1 trial

Macroglobulinemia1 trial

Supraclavicular Brachial Plexus Block1 trial